Novel Drug Discovery for the Treatment of Cancer
Welcome to Sentinel Oncology. Our aim is to discover new chemical entities for the use in better treatments for cancer.
Learn about our research and development
Become a Product Partner
Sentinel Oncology is seeking partners to out-license products from its oncology pipeline at the pre-clinical development phase.
The Sentinel pipeline contains a number of novel small molecule programmes designed to inhibit key targets important in cancer therapy including angiogenesis & invasion, DNA repair pathways and tumour hypoxia.
The CHK1 programme is currently undergoing pre-clinical evaluation following successful in-vivo proof of concept studies.
News
May 2009
Sentinel Oncology at BIO2009
Sentinel Oncology will be attending BIO Atlanta (18th-21st May 2009) and available for partnering discussions. Contact us… read more
February 2009
Sentinel Oncology Limited p70S6 kinase inhibitor licensing opportunity
Sentinel Oncology, the Cambridge based cancer company focused on the discovery of novel treatments for… read more
January 2009
Sentinel Oncology Appoints John Dixon To Board Of Directors
Sentinel Oncology is pleased to announce the appointment of Dr. John Dixon to the board of Directors.… read more